Lord, Abbett & Co
MLYS icon

Lord, Abbett & Co’s Mineralys Therapeutics MLYS Stock Holding History

Lord, Abbett & Co’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.15M Sell
300,913
-11,483
-4% -$337K 0.03% 390
2025
Q4 		$11.3M Buy
+312,396
New +$12.5M 0.03% 363

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Lord, Abbett & Co's MLYS Position: Q1 2026 in Review

Lord, Abbett & Co reduced its Mineralys Therapeutics (MLYS) stake by 3.7% in Q1 2026, selling an estimated $337K and leaving 300,913 shares worth $8.15M. The position accounts for 0.03% of the portfolio, ranked #390.

Lord, Abbett & Co first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $11.3M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Lord, Abbett & Co held 300,913 shares of Mineralys Therapeutics worth $8.15M as of Q1 2026.
  • Lord, Abbett & Co sold 11,483 Mineralys Therapeutics shares in Q1 2026, an estimated $337K.
  • Mineralys Therapeutics made up 0.03% of Lord, Abbett & Co's portfolio in Q1 2026, its #390 holding.
  • Lord, Abbett & Co first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Lord, Abbett & Co's Mineralys Therapeutics position peaked at $11.3M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Lord, Abbett & Co's 13F filing for Q1 2026, filed 14 May 2026.